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eATCHMAN for
troke Prevention:
n Out-of-Date Procedure
ith interest we read the article by Sick et al. (1) about the
ATCHMAN left atrial appendage (LAA) system for stroke
revention in atrial fibrillation (AF). We have concerns about the
ationale of this technique and questions about the results, which
rompt us to challenge the authors’ conclusion that LAA occlusion
ith the WATCHMAN system is safe and effective.
First, there is no evidence that thromboembolism in AF
xclusively derives from LAA thrombi detected by transesophageal
chocardiography (TEE). When prospectively investigating clini-
ally stable outpatients with AF and no recent embolism by TEE,
he prevalence of LAA thrombi was only 2.5%, and during a
ollow-up of 58 months, LAA thrombus did not predict stroke/
mbolism (2).
Second, the LAA has properties that render device implantation
ifficult and might impede patency of the occlusion. The LAA
yocardium has a higher distensibility than the left atrial myocar-
ium. This might induce oversizing of the device and lead to
ompression of neighboring structures like the circumflex branch
f the left coronary artery (3). Progressive dilation of the LAA
ccurs in AF, possibly leading to undersizing of the device and
eakage of a primarily completely closed LAA (3). Left atrial
ppendage–endocardial fibroelastosis, occurring frequently in AF,
akes fixation of the device difficult. The LAA is a place of
ecretion of atrial natriuretic peptide (ANP) (3). Possibly, contin-
ous ANP secretion into the LAA cavity even after closure might
ontribute to leakages.
Third, incomplete LAA closure creates a pouch with stagnant
lood flow, which enhances thrombus formation and might
ecessitate oral anticoagulation (OAC), although this was the
ntention to prevent first. Thus, we cannot understand why
ATCHMAN placement was assessed as “successful” even in
ases with a jet 3 mm around the device. In how many patients
ere small jets visible after implantation? And did the width of the
ets increase during follow-up? Were they associated with throm-
us formation or embolism?
How many patients were screened altogether? What was the
ind and frequency of exclusion criteria? The listed comorbidities
re frequent in AF patients and would thus prompt OAC.
Were the patients investigated by a neurologist and cranial-
omputed tomography or magnetic resonance imaging to look for
erebral ischemia? Which was the indication for warfarin therapy
n 8% of the patients at 6-month follow-up?
It is reported that embolized devices were retrieved percutane-
usly. In the meantime, embolization of a WATCHMAN device
as been reported, which could be retrieved only by surgery, where
t was removed from the aortic valve and an aortic bioprosthesis
nd a pacemaker had to be implanted (4). tEven if technical improvements would lead to a more effective
AA occlusion, potential further side effects have to be considered.
he LAA plays an important role in hemodynamic and body fluid
egulation (3). Left atrial appendage elimination might impede
hysiologic regulations of heart failure and thirst perception. The
NP contributes to physiological control of lipid mobilization in
umans, whereas LAA elimination might promote development
f obesity (5). In view of global warming and the obesity epidemia,
AA elimination has to be strongly questioned as a beneficial
rocedure for stroke prevention in AF patients living in the 21st
entury.
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eply
lthough we are pleased that Drs. Stöllberger and Finsterer read
ur article with interest, their letter titled “An Out-of-Date-
rocedure” seems to be part of their series of editorials against left
trial appendage (LAA) occlusion, made particularly odd in this
nstance by the claim that use of these devices will contribute to the
besity epidemic and global warming. We are also puzzled by the
haracterization of this technology as “out of date,” considering
hat it is currently undergoing its first randomized prospective trial.
Drs. Stöllberger and Finsterer state that they are prompted “to
hallenge the authors’ conclusion that LAA occlusion with the
ATCHMAN system is safe and effective.” We are unable to
nd any allusion to “safe and effective” in our report (1). Claims for
fficacy are not, as they might not be aware, designed into pilot
rials. Indeed we were careful to state that the study was not
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August 28, 2007:914–5owered to address efficacy and that the data are preliminary,
uggesting safety and feasibility only. We hope safety and efficacy
ill be shown by the randomized PROTECT-AF pivotal trial,
ith currently over 400 patients enrolled (2).
With regard to the prevalence of thrombus in the LAA in
n-anticoagulated patients, the rate of 2.5% to which the letter’s
uthors allude comes from their data (3) and varies from the rest of
he published data, reporting left atrial thrombus in up to 25% of
n-anticoagulated atrial fibrillation (AF) patients (4–6). Their
oncerns relating to possible significance of the proximity of the
ircumflex coronary artery, possible undersizing of devices, poten-
ial difficulties with device fixation, and leakage “of a primarily
ompletely closed LAA,” although important to consider, are
ased only on speculation, in some cases refer to the surgical rather
han percutaneous experience, and have as yet no evidence base for
upport. Drs. Stöllberger and Finsterer do reference their case
eport of a patient with device embolization who was not part of
his trial. We are puzzled by their pre-publication of that particular
ase despite its being part of an ongoing study in which they have
o involvement.
Our study was too small to address a number of their queries
hat will be part of the analysis of the large pivotal study under way.
s the authors must be aware, pilot trials generally exclude the
ighest-risk patients, in this case so as not to withhold anticoag-
lation until feasibility is shown. Regardless, the patient popula-
ion in our pilot study is from a vast pool of AF patients, the
ajority of whom worldwide are not anticoagulated, despite the
ell-reported 6:1 ratio of embolic events in the absence of
nticoagulation (7).
We are pleased to have in common with Drs. Stöllberger and
insterer our considerable enthusiasm for eliminating the obesity
nd global warming epidemics, but their implicating LAA-
cclusion in these “epidemia” is, like their letter, a bit extreme. Far
rom needing to be “strongly re-considered,” the device is just now
eing considered in the first place with the crucible of a carefully
7esigned, conducted, and monitored randomized trial. If the
ATCHMAN is in fact safe and effective, it has the potential of
ontributing uniquely to the welfare of AF patients. We look
orward to analyzing those results based on the scientific method.
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